Physician profile
Joel Arter
NPI 1942512744
$663.90
in general payments reported to CMS, 2019-2025
12 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.84 · 2023: $130 · 2024: $309 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.21 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150.76 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $94.52 | 2021-2024 | Mounjaro, Jardiance |
| Phadia US INC. | $93.00 | 2023-2024 | Immunocap |
| Cranial Technologies, INC | $68.11 | 2024-2025 | Doc Band |
| Hologic Sales and Service, LLC | $52.44 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.71 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $39.92 | 2023 | Breztri |
| Alkermes, INC. | $34.81 | 2024 | Vivitrol |
| Abbott Laboratories | $25.64 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $21.89 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $19.33 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Cipher Pharmaceuticals US LLC | $13.77 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Arter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.